What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)
CSI Rome Manon Slob and Shahnam Sharif extensively discuss the results of the EMPA-REG OUTCOME study, the first outcomes trial with an SGLT2 inhibitor, with Prof. Silvio Inzucchi (New Haven, CT, USA), including what the results may mean for the management of diabetes.
- A summary of the rationale and results of the EMPA-REG OUTCOME trial on use of empagliflozin in diabetes 0:31
- Did we need yet another class of glucose-lowering medication? 5:13
- Can SGLT2 inhibitors be given to patients with decreased kidney function? 7:09
- The potential underlying cardioprotective mechanisms. 7:59
- Potential risks or adverse effects associated with use of these agents. 9:47
- How could these data influence the guidelines, or what other data do we need? 11:02
In the Cardiovascular Scene Investigation (CSI) series, young clinicians with an investigative mindset interview experts about the context and meaning of the results they just presented at the ESC congress.
The series is aimed to explore the background and practical implications of recent scientific developments, like those discussed in the Educational Programme session called 'A perspective on the effects of Empaglifozin in cardiovascular outcomes' at the ESC Congress 2016, with speakers in this session.
Faculty & Disclosures
Silvio Inzucchi - Professor of Medicine (Endocrinology); Clinical Director, Section of Endocrinology; Medical Director, Yale Diabetes Center; Director, Endocrinology & Metabolism Fellowship; Director, Yale Affiliated Hospitals Program, Yale School of Medicine, New Haven, CT USA
Manon Slob and Shahnam Sharif - UMC Utrecht, The Netherlands
The speakers did not receive financial compensation for participating in these interviews